Auxilium Health Secures $3.4 Million to Accelerate Bioaerogel Platform

For forty years, medical science has struggled with the "race for the surface," a competition where bacteria often colonize surgical implants before a patient's own cells can begin the healing process. Auxilium’s Aer™ technology attempts to bypass this by utilizing an engineered matrix that mimics the body’s natural extracellular structure. By resisting bacterial attachment while simultaneously encouraging regenerative cell growth, the product functions without the need for traditional antibiotics.

This influx of capital follows a year of significant expansion for the firm, which has doubled its full-time staff and attracted specialized researchers to its headquarters at the Cleveland Clinic’s Global Innovation Center. According to CEO Isaiah Kaiser, the company has shifted its focus from proving the underlying science to refining the speed of clinical implementation. Supported by the National Science Foundation and state development grants, the team is now preparing to transition its lead product from the lab to the operating room.